Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 15.

Bachmann, M F; Kündig, T M (2017). Allergen-specific immunotherapy: is it vaccination against toxins after all? Allergy, 72(1):13-23.

Kündig, T M; Klimek, L; Schendzielorz, P; Renner, W A; Senti, G; Bachmann, M F (2015). Is the allergen really needed in allergy immunotherapy? Current Treatment Options in Allergy, 2:72-82.

Uermösi, C; Zabel, F; Manolova, V; Bauer, M; Beerli, R R; Senti, G; Kündig, T M; Saudan, P; Bachmann, M F (2014). IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. Allergy, 69(3):338-347.

Fettelschoss, A; Kistowska, M; LeibundGut-Landmann, S; Beer, H D; Johansen, P; Senti, G; Contassot, E; Bachmann, M F; French, L E; Oxenius, A; Kündig, T M (2011). Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proceedings of the National Academy of Sciences of the United States of America, 108(44):18055-18060.

Freigang, S; Ampenberger, F; Spohn, G; Heer, S; Shamshiev, A T; Kisielow, J; Hersberger, M; Yamamoto, M; Bachmann, M F; Kopf, M (2011). Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. European Journal of Immunology, 41(7):2040-2051.

Röhn, T A; Ralvenius, W T; Paul, J; Borter, P; Hernandez, M; Witschi, R; Grest, P; Zeilhofer, H U; Bachmann, M F; Jennings, G T (2011). A Virus-Like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain. Journal of Immunology, 186(3):1769-1780.

Guler, R; Parihar, S P; Spohn, G; Johansen, P; Brombacher, F; Bachmann, M F (2011). Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine, 29(6):1339-1346.

Speiser, D E; Schwarz, K; Baumgaertner, P; Conzett, K B; Manolova, V; Devevre, E; Sterry, W; Walden, P; Zippelius, A; Senti, G; Voelter, V; Cerottini, J P; Guggisberg, D; Willers, J; Geldhof, C; Romero, P; Kündig, T; Knuth, A; Dummer, R; Trefzer, U; Bachmann, M F (2010). Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of Immunotherapy, 33(8):848-858.

Kündig, T M; Bachmann, M F (2010). Allergen-specific immunotherapy: Regulatory T cells or allergen-specific IgG? Human Vaccines, 6(8):673-675.

Uermösi, C; Beerli, R R; Bauer, M; Manolova, V; Dietmeier, K; Buser, R B; Kündig, T M; Saudan, P; Bachmann, M F (2010). Mechanisms of allergen-specific desensitization. Journal of Allergy and Clinical Immunology, 126(2):375-383.

Senti, G; Johansen, P; Haug, Susanne; Bull, C; Gottschaller, C; Müller, P; Pfister, T; Maurer, P; Bachmann, M F; Graf, N; Kündig, T M (2009). Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clinical and Experimental Allergy, 39(4):562-570.

Fulurija, A; Lutz, T A; Sladko, K; Osto, M; Wielinga, P Y; Bachmann, M F; Saudan, P (2008). Vaccination against GIP for the treatment of obesity. PLoS ONE, 3(9):3163.

Spohn, G; Keller, I; Beck, M; Grest, P; Jennings, G T; Bachmann, M F (2008). Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. European Journal of Immunology, 38(3):877-887.

Sirena, D; Lilienfeld, B; Eisenhut, M; Kälin, S; Boucke, K; Beerli, R R; Vogt, Lorenz; Ruedl, C; Bachmann, M F; Greber, U F; Hemmi, S (2004). The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. Journal of Virology, 78(9):4454-4462.

Storni, T; Ruedl, C; Schwarz, K; Schwendener, R; Renner, W A; Bachmann, M F (2004). Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. Journal of Immunology, 172(3):1777-1785.

This list was generated on Fri Oct 20 02:28:07 2017 CEST.